Navigation Links
SyntheMed, Inc. Adopts Shareholder Rights Plan
Date:5/20/2008

ISELIN, N.J., May 20 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that its Board of Directors approved the adoption of a shareholder rights plan. The shareholder rights plan is designed to ensure that shareholders realize fair value and equal treatment in the event of an attempted takeover of the company and to protect the company and its shareholders against coercive takeover tactics. The plan was not approved for adoption as a result of any specific takeover attempt.

To implement the shareholder rights plan, the Board of Directors has declared a dividend distribution of one right for each share of SyntheMed common stock outstanding as of the close of business on June 2, 2008. Initially, the rights will be represented by SyntheMed common stock certificates, will not be traded separately from the common stock and will not be exercisable. The rights generally will become exercisable following any person becoming an "acquiring person" by acquiring, or commencing a tender offer to acquire, beneficial ownership of 15% or more of the outstanding shares of SyntheMed common stock. If a person becomes an "acquiring person," each holder of a right, other than the acquirer, would be entitled to receive, upon payment of the then purchase price, a number of shares of SyntheMed common stock or other securities having a value equal to twice the purchase price. If SyntheMed is acquired in a merger or other business combination transaction after any such event, each holder of a right, other than the acquirer, would be entitled to receive, upon payment of the then purchase price, shares of the acquiring company having a value equal to twice the purchase price. The rights are scheduled to expire on June 2, 2018 unless earlier redeemed, terminated or exchanged in accordance with the terms of the shareholder rights plan.

In connection with the adoption of the rights plan, a committee of the Board of Directors comprised of independent directors is to review the rights plan at least once every three years to determine whether maintaining the rights plan continues to be in the best interests of the company and its stockholders.

The rights plan and the terms of the rights are governed by a rights agreement dated May 20, 2008 between SyntheMed and its transfer agent. The foregoing description of the rights plan does not purport to be complete and is qualified in its entirety by reference to the full text of the rights agreement, which will be filed with the Securities and Exchange Commission.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products, drug delivery products and other surgical implants. The company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
2. Virginias largest Cardiac Surgery program adopts SPY as standard of care
3. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
4. Indiana Adopts Legislation to Combat Illegitimate Online Pharmacies, Protect Residents From Counterfeit Drugs
5. Weight Watchers COO Adopts 10b5-1 Trading Plan
6. Masimo Corporation Adopts Stockholder Rights Plan
7. APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene
8. Texas Health and Human Services Commission Adopts Mediwares ClosedLoop(TM) Medication Management Strategy
9. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
10. Aionex Adopts SkyeTeks Embedded RFID Solution to Ensure Patient Safety
11. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center ... be awarded for the fall semester to a deserving student. Get your applications ... 2017 scholarship was awarded to Mariana Castillo who is a nursing student at Prairie ...
(Date:7/24/2017)... Los Angeles, California (PRWEB) , ... July 24, ... ... office building fire in Oakland, California effectively destroyed the construction site and threatened ... to a July 7th article on NBCLosAngeles.com. Los Angeles Area ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , ... announced it has partnered with WALLIX to expand its solution to help ... , There are a number of ways to address the authentication requirements within ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global ... the issuance of United States Patent Number 9,695,398 (the '398 patent) and South ... The '398 and '324 patents cover methods and systems for optimizing fat grafts ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology: